MYC amplifies mitotic perturbations elicited by LXY18 to enable synthetic lethality

The MYC oncoprotein represents an intriguing target for cancer treatment, but its therapeutic potential has been hindered by the absence of specific pharmacological inhibitors. In this study, we demonstrate that the phenoxy quinoline compound LXY18 selectively targets and eliminates cells overexpressing MYC, leaving non-transformed cells unharmed. This synthetic lethality arises from an acute induction of multipolarity, resulting in a persistent arrest in early mitosis followed by cell death in mitosis or after mitotic slippage. Distinctively, LXY18's action contrasts with other antimitotic compounds, as they either fail to induce mitotic arrest or elicit mitotic arrest irrespective of MYC abundance. Furthermore, the MYC abundance in a panel of 98 tumor cell lines correlates with their sensitivity to LXY18. Collectively, our findings uncover LXY18 as an MYC-enabled mitotic blocker and open a new avenue to selectively target MYC-overexpressing tumor cells without affecting normal cells. ### Competing Interest Statement The authors declare the following competing financial interest. Anticancer Bioscience has submitted intellectual property filings (PCT/CN2021/091425 and PCT/CN2021/127309) that cover LXY18. Dr. Dun Yang is a founder and shareholder of ACB.